1. Anon. (2001) ICHS7A: Safety pharmacology studies for human pharmaceuticals. CPMP/ICH/539/00. London.
http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002831.pdf
. Accessed 11 Dec 2013
2. Anon. (2012) Guidance document 116 on the conduct and design of chronic toxicity and carcinogenicity studies, supporting test guidelines 451, 452 and 453 – 2nd edition. OECD Environment, Health and Safety publications (series on testing and assessment), Paris.
http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011)47&doclanguage=en
. Accessed 11 Dec 2013
3. Arrowsmith J (2011) Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10(5):328–329
4. Arrowsmith J, Miller P (2013) Trial watch: Phase II and Phase III attrition rates 2011–2012. Nat Rev Drug Discov 12:569
5. Bankir L, de Rouffignac C (1985) Urinary concentrating ability: insights from comparative anatomy. Am J Physiol 249(6 Part 2):R643–R666